Outlook Therapeutics has historically not generated net operating profits, recording consistent net losses typical of clinical-stage biotechnology firms that invest heavily in multi-year clinical trials, regulatory submissions, and commercial launch preparation before achieving sustainable product revenue streams and positive cash flows.